NCT06842589View on ClinicalTrials.gov

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 14, 2025

Primary Completion Date

February 14, 2027

Study Completion Date

January 31, 2028

Conditions
Multi-Drug Resistant Nephrotic SyndromeCAR-T Cell Therapy
Interventions
BIOLOGICAL

anti-CD19 CAR-T cells

Three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.

Trial Locations (1)

310000

RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER

NCT06842589 - Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS | Biotech Hunter | Biotech Hunter